X

Trial Profile

A Long-Term, Open-Label, Safety, Tolerability and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mercaptamine bitartrate (Primary)
Indications Cystinosis
Focus Therapeutic Use
Sponsors Raptor Pharmaceutical Inc

Most Recent Events

26 Jul 2017 Status changed from active, no longer recruiting to completed.
14 Jul 2017 Results published in the Horizon Pharma plc media release.
14 Jul 2017 According to a Horizon Pharma plc media release, the company presented result of Halitosis Substudy (n=20) at the Cystinosis Research Network (CRN) 2017 Family Conference.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com